References

H
Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502-2509.
Hézode C, Lebray P, de Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme [Epub ahead of print]. Liver Int. 2017;37(9):1314-1324.
Hezode C, Reau N, Svarovskaia ES, et al. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018;68(5):895-903.
Higley C, Hsu CC, Smith C, Nadella S, Lalos AT. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports. World J Hepatol. 2020;12(12):1341-1348.
Ho SB, Brau N, Cheung R, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol. 2015;13(11):2005-2014.e1-3.
Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020-1031.
Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861.
Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-609.
Honegger JR, Kim S, Price AA, et al. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med. 2013;19(11):1529-1533.
Honegger J, Crim L, Gowda C, Sanchez PJ. Polymerase chain reaction (PCR) for detection of vertically-acquired hepatitis C virus (HCV) infection in early infancy [abstract 2215]. ID Week. 2018.
Hoornenborg E, Achterbergh RCA, Schim van-der-L, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection:. AIDS. 2017;31(11):1603-1610.
Hoornenborg E, Coyer L, Boyd A, et al. Amsterdam PrEP project team in the HIV transmission elimination Amsterdam (H-TEAM) initiative. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. J Hepatol. 2020;72(5):855-864.
Hosein SR, Wilson DP. HIV, HCV, and drug use in men who have sex with men. Lancet. 2013;382(9898):1095-1096.
Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29(4):1215-1219.
Houssel-Debry P, Coilly A, Fougerou-Leurent C, et al. 12 weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology. 2018;68(4):1277-1287.
Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59(12):1657-1665.
Hsieh YH, Rothman RE, Laeyendecker , et al. Evaluation of the Centers for Disease Control and Prevention recommendations for hepatitis C virus testing in an urban emergency department. Clin Infect Dis. 2016;62(9):1059-1065.
Hsu L, Bowlus CL, Stewart SL, et al. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci. 2013;58(3):807-814.
Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59(4):1293-1302.
Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503.
Top